SMS Pharmaceuticals books ₹87.61 cr annual profit
Annual results confirm steady growth with a final dividend of ₹0.40 per share.
— 2 earlier stories on SMS Pharmaceuticals Ltd. →What's new
- Standalone revenue hit ₹886.87 cr, rising 13.3% from the prior year.
- The board declared a final dividend of ₹0.40 per share.
- Administrative updates include a change in registered office and auditor appointments.
Why it matters
The company met the expectations set in its previous quarterly updates. With no material surprises, this release confirms a steady performance trajectory.
What we're watching
- Sustainability of current profit margins.
- Product mix shifts in the new fiscal year.
- Execution of capacity expansion.
The full read
SMS Pharmaceuticals closed the fiscal year with ₹886.87 crore in standalone revenue and ₹87.61 crore in net profit. These figures mark a 13.3% and 28.1% increase over the previous year. The board recommended a final dividend of ₹0.40 per share, accompanied by routine administrative changes such as an auditor appointment and an office relocation. This disclosure contains no surprises. It confirms the growth trends outlined in the company’s earlier quarterly reports. The open question is whether these margins persist in the coming year. What changes from here is the company's ability to maintain this pace as it scales production.